Plasma Fractionation Market Set for Major Expansion by 2035
New York, Wednesday, 3 September 2025.
The plasma fractionation market is expected to grow significantly, driven by increased demand for immunoglobulins and plasma-derived therapies, with projections reaching $12.7 billion by 2035.
Rising Demand for Plasma-Derived Therapies
The plasma fractionation market is projected to experience significant growth, with a Compound Annual Growth Rate (CAGR) of 9.2% from 2025 to 2035. This growth is largely driven by the increasing demand for plasma-derived therapies, particularly immunoglobulins, which are essential for treating a variety of disorders such as oncological, hematological, pulmonary, and immunological conditions. By 2035, the market is expected to reach a valuation of $12.7 billion, up from $5.3 billion in 2025 [1].
Strategic Investments and Market Expansion
To meet the rising demand, plasma fractionators are heavily investing in expanding their capabilities. Approximately 30% of these expansion initiatives are taking place in North America, underscoring the region’s strategic importance in the global plasma fractionation landscape [1]. The market’s growth is further bolstered by a steady increase in mergers and acquisitions, particularly among players based in Europe. This consolidation trend highlights a strategic realignment aimed at enhancing production capacities and optimizing supply chain efficiencies [1].
Key Players and Technological Advancements
Major companies such as Baxter, Grifols, Kedrion, Octapharma, CSL, and Takeda Pharmaceutical are at the forefront of the plasma fractionation market. These key players are leveraging technological advancements to improve the safety and efficacy of plasma-derived products. Innovations in viral inactivation and pathogen removal techniques are enhancing the product safety profile, reducing reliance on plasma donations, and paving the way for the development of recombinant protein alternatives [1][2].
Global Market Dynamics and Regional Insights
The global plasma fractionation market is currently dominated by Europe, which holds the largest market share. However, the Asia-Pacific region is anticipated to witness the fastest growth, driven by expanding healthcare infrastructure and an increasing prevalence of chronic and rare diseases. This growth is expected to challenge the current market leaders and drive significant investments in the region’s healthcare sector [1][3].